biostudies-literaturevan Berge Henegouwen JMBristol-Myers SquibbBayerPfizer PharmaceuticalsEisaiThe Hartwig Medical FoundationNovartisRocheClovis OncologyBoehringer IngelheimBarcode for Life FoundationAstraZenecaLillyAmgen NederlandJanssen PharmaceuticalsKWF KankerbestrijdingMerck Sharp and Dohme97-104https://www.ebi.ac.uk/biostudies/studies/S-EPMC9300506biostudies-literatureUnknown90(1)<h4>Introduction</h4>The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutations in other tumor types, including thyroid carcinoma. Since thyroid carcinoma is not a labeled indication for BRAF/MEKi, a cohort for patients with BRAF V600-mutated thyroid carcinoma was opened within the Drug Rediscovery Protocol (DRUP), a national ongoing pan-cancer multi-drug trial, in which patients receive off-label treatment with approved drugs based on their molecular tumor profile.<h4>Results</h4>Here, we present two patients with BRAF-mutated thyroid carcinoma, who were successfCancer chemotherapy and pharmacologyEfficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.PMC930050610014van Berge Henegouwen JMMeertens MZeverijn LJVerheul HMWGelderblom HHuitema ADRLabots Mvan der Wijngaart HHoes LRDevriese LAVoest EEfalseEfficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.<h4>Introduction</h4>The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutations in other tumor types, including thyroid carcinoma. Since thyroid carcinoma is not a labeled indication for BRAF/MEKi, a cohort for patients with BRAF V600-mutated thyroid carcinoma was opened within the Drug Rediscovery Protocol (DRUP), a national ongoing pan-cancer multi-drug trial, in which patients receive off-label treatment with approved drugs based on their molecular tumor profile.<h4>Results</h4>Here, we present two patients with BRAF-mutated thyroid carcinoma, who were successf2022-01-01T00:00:00Z2022 Jul2025-04-25T18:10:39.324Z2024-11-15T12:30:28.778ZS-EPMC93005063559818610.1007/s00280-022-04437-z